Background. Lower incidence and severity of acute graft versus host disease (GVHD) has been observed in leukemia patients receiving HLA-mismatched umbilical cord (UCB) transplants. However, despite the increased use of UCB in stem cell transplantation, the mechanisms underlying these favorable outcomes are not well delineated. Methods. We analyzed antigen specific lymphocyte responses after transplant to determine whether the decreased allogeneic responsiveness of UCB lymphocytes is attributable to pan-unresponsiveness, lymphocyte repressive or recipient-specific tolerance. Results. Circulating lymphocytes collected early (3 months) after UCB transplant demonstrate a less naïve phenotype compared with that in the infused graft. Additionally, after transplant, circulating peripheral blood UCB-derived lymphocytes produced normal levels of interferon-␥ and proliferated normally when stimulated with mitogen or third party alloantigen. In contrast, when stimulated with recipient antigen, circulating lymphocytes emerging posttransplant did not proliferate nor produce interferon-␥. Moreover, analysis of interleukin-4 production revealed a Th2 response to recipient antigens. These data indicate early induction of immune tolerance of naïve UCB graft lymphocytes with skewing of transplant recipient-specific immune response towards Th2 cytokine profile. Conclusions. UCB graft lymphocyte immune naivety and observed early tolerance induction may contribute to the observed favorable GVHD incidence, despite infusion of HLA mismatch grafts in the unrelated allogeneic setting.
A llogeneic bone marrow transplantation (BMT) is an effective medical therapy for life-threatening hematologic disorders (1) . However, use of BMT is limited by lack of available human leukocyte antigen (HLA)-matched donors. Umbilical cord blood (UCB) has emerged from this background as an alternative stem cell source due to its ready availability and its effectiveness despite HLA-disparity of one or more antigens (2) (3) (4) (5) .
Graft versus host disease (GVHD), a major impediment to successful allogeneic stem cell transplantation, is mediated by donor T-cell alloreactivity directed against major and minor histocompatibility antigens presented by recipient antigen presenting cells. In addition, recent studies have identified a potential role of early recovering natural killer (NK) cells expressing killer immunoglobulin-like receptors (KIR) in mitigating GVHD immune reactivity at early time points after allogeneic transplant (6) . A third important lymphocyte population participating in allogeneic reactivity include Tregulatory cells, which have been shown to inhibit immune responses in vivo after allogeneic BMT in murine models (7) . Whether or not a patient develops GVHD is determined by the interactions of these donor immune cells with recipient antigen presenting cells.
Clinical reports identify that despite infusion of HLAdisparate lymphocytes, UCB grafts elicit low rates of acute GVHD, possibly due to the immune naivety of the infused neonatal T cells (2, 3, 8 -12) . UCB contains approximately 30 -50% CD3
ϩ T-cells with predominant CD45RA ϩ naïve phenotype. It has been shown that activated UCB T-cells produce lower amounts of Th1 and Th2 cytokines after in vitro stimulation as compared to adult T-cells, including interferon-␥ (IFN-␥) and tumor necrosis factor-␣ (TNF-␣), cytokines known to play an important role in amplifying T-cell allogeneic responses, and contributing to clinical manifestations of GVHD (13, 14) . Moreover, although UCB T-cells proliferate at rates equivalent to adult T-cells in response to primary stimulation, alloantigen-specific cytotoxicity is reduced in UCB T-cells after secondary stimulation (15, 16) .
This report outlines studies focused on immune reactivity measured in adults with hematologic malignancies treated with myeloablative conditioning and infused with banked unrelated allogeneic HLA-disparate neonatal UCB stem cell grafts. We report herein, lymphocyte analyses performed on UCB grafts and their progeny emerging in adult hematology patients within the first 3 months after infusion. We hypothesize that infused UCB graft lymphocytes may have the capability of developing tolerance to recipient anti-gens, accounting in part for clinical observations of reduced GVHD in cord blood transplant recipients. We therefore analyzed lymphocyte surface phenotypes and functionality including responsiveness to recipient antigens 3 months after UCB transplant. Immunophenotyping studies revealed a maturation of the UCB donor-derived T cells from naïve (CD45RA) to memory (CD45RO). Lymphocyte proliferation and cytokine production studies revealed that although a robust response to third party antigens and/or mitogen stimulation by the UCB donor lymphocytes was maintained, there was reduced immune response overall to patient antigens. Our results suggest recipient immune tolerance induction over pan-unresponsiveness lymphocyte suppression or lymphocyte suppression exhibited by donor-derived lymphocytes emerging at early time points after HLA mismatched unrelated UCB allogeneic stem cell transplant.
PATIENTS AND METHODS

Patients, UCB Grafts, and Sample Collection
The Institutional Review Board of Case Western Reserve University/University Hospitals of Cleveland approved the clinical protocol for UCB transplantation; written informed consent was obtained from all patients. Study patients included adults with hematologic malignancies consecutively treated with full myeloablative conditioning regimens; followed by transplants of single unit HLA-mismatched umbilical cord blood, which was thawed and directly infused without in vitro expansion. Graft selection, HLA typing, cord blood processing, preparative regimens, transplantation procedure, supportive care and prophylaxis against GVHD were performed as previously described (9) . Chimerism was evaluated in all study patients by fluorescent in situ hybridization (FISH) for the Y chromosome in sex-mismatched transplants, or DRB1 allele-specific hybridization in cases in which the donor and patient differed at HLA-DR, or use of quantitative PCR for microsatellite DNA markers.
Cells
Peripheral blood was collected from transplant patients and healthy adult donors, and peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Histopaque (1.077 g/ml) (Sigma Chemical, St. Louis, MO) density gradient centrifugation, and cryopreserved with 10% v/v dimethylsulfoxide until further study. Peripheral blood from UCB transplant recipients was collected prior to administration of myeloablative regimen and transplantation as well as 3 months after transplant. To ensure consistency within stimulator lymphocyte populations, irradiated (100 Gy) cloned homozygous HLA-DRB1*0101-positive EBV-transformed positive B cell clone, LG2 was used (National Institute of Cancer Research, Genoa, Italy) (17) (18) (19) . LG2 cells were HLA typed and compared with UCB graft and study patient HLA genotypes; LG2 cells were HLA disparate with all study patients and UCB grafts. Of 20 patients consecutively transplanted at this institution, experiments and data presented were performed on nine patients surviving at the time of study.
MLC ELISPOT Assays and Proliferation Assay
The assays were performed as described previously (20) . Briefly, ImmunoSpot plates P50 or M200 (Cellular Technology Ltd, Cleveland, OH) were coated overnight at 4°C with capture antibodies (Ab) that were specific for either IFN-␥ 2G1 (Endogen, Woburn, MA) at 2 g/ml or anti-interleukin-4 (IL-4) Ab 8D4-8 (BD PharMingen, San Diego, CA) at 4 g/ml. The plates were blocked with BSA (10 g/L in PBS).
Mixed lymphocyte cultures (MLC) were performed using patient's PBMC, obtained 3 months after transplant or healthy adults as responders. Stimulator cells included either: a) recipient PBMC collected from the respective patient prior to myeloablative regimen and transplantation (host), or b.)
LG2 cells (3rd-party). Stimulator cells were irradiated (30Gy) and incubated with responder cells in complete RPMI media (94% RPMI ϩ 5%ABO serum ϩ 1% L-glutamine). The responder/stimulator ratio was 1:1, plating 0.1 or 0.3ϫ 10 6 cells/well as indicated, in triplicate. Responder PBMC activated with phytohemagglutinin (PHA) (Sigma Chemical) at 10 g/ml final concentration served as positive controls. Negative control wells contained responder PBMC in media alone. After 24h for IFN-␥ assays, or after 48 h for IL-4 assays, the plates were washed and biotinylated detection antibodies were added for 12h, at 4°C. The following monoclonal Abs were used: IFN-␥ (B133.5 Endogen) at 2 g/ml and IL-4 (MP4-25D2 PharMingen) at 3 g/ml. The plates were developed for 10 -20 min for IFN-␥ assays, and 45-60 min for IL-4 assays. The plates were air dried overnight and subjected to image analysis using an ImmunoSpot Image Analyzer (Cellular Technology, Cleveland, OH). For the proliferation assays the setup was identical as above only that the cells were plated in 96 well round-bottom tissue culture plates (Costar, Corning, NY) and after a 4 day culture 1 Ci 
Flow Cytometric Analysis and Cell Separation
UCB graft mononuclear cells and PBMC from patients at 3 months after transplant were stained for 30 min on ice with the following antibodies and appropriate isotype controls: CD3, CD4, CD8, CD34, CD45RO, CD45RA, and CD45 (Becton Dickinson, San Jose, CA and Beckman-Coulter, Fullerton, CA); added in four-color combinations (FITC, PE, PerCP and APC). Minimum 20,000 events were acquired on an Elite ESP flow cytometer (Coulter, Miami, FL) and analyzed with WinList (Verity Software House Inc, Topsham, MN). In T-cell selection studies, CD3 ϩ cells were isolated from PBMC by negative selection using RosetteSep enrichment cocktails (Stemcell Technologies, Vancouver). The Tcell depletion cocktail (RosetteSep) was also used to select antigen presenting cells (APC). The specified cell fractions isolated were of Ͼ96% purity confirmed by flow cytometry (data not shown).
RESULTS
Patients and Outcomes
This study included nine evaluable adult patients with hematologic malignancies of an initial cohort of 20 patients enrolled in a single institution phase I clinical trial who were consecutively transplanted with HLA-mismatched unrelated UCB after receiving full ablative conditioning, and who engrafted and survived Ͼ90 days. Patient and graft characteristics and transplant outcomes are shown in Tables 1-3 . All patients underwent UCB transplantation for treatment of high risk or recurrent leukemia (Table 1) . UCB donor-derived neutrophil engraftment (ANCϾ500x10 9 /L) occurred on average 25 days after transplant (range: 13-36) ( Table 2) . Severe acute GVHD (grades III-IV) was observed in only 3 patients despite infusion of UCB grafts mismatched at Ն1 HLA loci. Five patients are alive and event free at median follow up 38 months (range 10 -74 months).
Graft Analysis
UCB graft analyses included HLA analyses, and surface immunophenotyping prior to infusion, according to methods previously described (9) . The infused UCB grafts were HLA mismatched in all patients, including: 3/6 matched loci in 2 patients, 4/6 in 6 patients, and one patient received a 5/6 HLA matched graft ( Table 2 ). The median dose of CD34 ϩ and total nucleated cells infused were: 0.839 CD34 ϩ /kg recipient weight (range 0.366 -1.16) and 1.75ϫ10 7 cell/kg (range 1.22-4.51) respectively (Table 2) . HLA disparities were restricted to class I loci in 4 patients while 5 patients received grafts disparate at class I and class II (DRB1) loci. Notably, though UCB CD34 ϩ median cell dose was one log lower than conventional bone marrow grafts, median CD3 ϩ infused cell dose: 5.4x10 6 (range 4.47-27.4), was comparable to standard marrow graft infusions (Table 2) (21). PBMC were collected from all patients at 3 months after UCB stem cell transplant and surface immunophenotyping was performed. Full donor chimerism (Ͼ98% donor) was noted in PBMC in all transplant patients (Table 3) . CD4, CD8, CD45RA and CD45RO expression on the circulating UCB donor-derived T-cells measured at 3 months after transplant were compared with that initially infused in the UCB stem cell graft (Fig. 1A-D) . UCB graft infused CD3ϩ T-cells expressed predominantly CD4 phenotype (Fig. 1A) , while in two patients this shifted towards CD8 expression at 3 months posttransplant (Fig. 1B) . Interestingly, while infused UCB graft lymphocytes expressed predominantly naive CD45RA phenotype with very few CD45RO cells (Fig. 1C) , percentages of CD45RO ϩ lymphocytes were significantly (Pϭ0.0024) increased in circulating UCB donor-derived T-cells at early time points (3 months) after UCB stem cell graft infusion (Fig. 1D) . Absolute lymphocyte counts normalized in the majority (nϭ6) of the 9 study patients at time points 3 months posttransplant, when immunophenotyping and functional MLC were performed, with median counts 1.20x10 9 /L (range: 0.126-4.32x10 9 /L) in the entire cohort.
Immune Response Assays
The functional characteristics of early post engraftment circulating lymphocytes were tested by measuring their capability to produce IFN-␥ in mixed lymphocyte culture. We performed ELISPOT assays (20) to measure mitogen (PHA) and allogeneic stimulation-induced IFN-␥ production by PBMC collected from UCB transplant patients 3 months after transplant.
To verify T-cell specificity of IFN-␥ production observed upon mitogenic and allogeneic stimulation and to exclude possible production by monocytes, B and/or NK cells present in PBMC, T cell separation experiments were performed. ELISPOT assays were conducted to compare responses of whole PBMC with that of purified T-cells in combination with irradiated autologous antigen-presenting cells (APC) and APC alone from one representative UCB study patient (whom had sufficient available cells) at day 90 after transplantation ( Fig. 2A) . After 24h of PHA stimulation, PBMC (striped bars) and selected T-cells stimulated with autologous irradiated APC (full bars) contained equivalent numbers of IFN-␥ producing cells, while APC alone (empty bars) produced no significant IFN-␥, thus confirming T-cellspecificity of the observed IFN-␥ production ( Fig. 2A) . The same T-cell-specificity of IFN-␥ production was observed after 24h of allogeneic stimulation with LG2 cells. Within allogeneic stimulated APC, no IFN-␥ producing cells were observed ( Fig. 2A) . Equivalent results of unselected PBMC, T-cell and APC IFN-␥ producing cells were measured in healthy controls (data not shown). Both patient and healthy control results confirm T-cell specificity of the IFN-␥ production during allogeneic stimulation of whole PBMC.
Subsequent experiments were performed with mixed lymphocyte cultures with UCB donor-derived study patients' PBMC as responder cells (without T-cell separation) to minimize cell loss for complete analyses. UCB donor-derived PBMC from study patients were assessed for their capability to produce IFN-␥ after PHA stimulation by ELISPOT (Fig.  2B ). All patients displayed significant numbers (median 1,079 spots/10 6 PBMC plated, range 100-1,870 spots/10 6 PBMC) of IFN-␥ producing cells, comparable to responses observed in healthy adults (22) . This assay demonstrates that all of the patient cells tested had the capacity to produce IFN-␥ upon stimulation, indicating that lack of IFN-␥ production is not an artifact of the study method but a specific response.
Further experiments were performed to characterize the reactivity of newly circulating donor lymphocytes towards the transplant recipient antigens, and compared with responses to third party HLA disparate antigens. Th1/Th2 cytokine profiles and proliferative response of early circulating lymphocytes in UCB transplant patients were measured in MLC. Responder cells included PBMC collected from UCB transplant patients (nϭ3) at 3 months after graft infusion, stimulated with either: 1) irradiated host PBMC (collected from the respective patients pretransplant), or 2) third-party allogeneic irradiated LG2 B cell stimulator cells. ELISPOT assays were performed for IFN-␥ producing cells after 24h, or for IL-4 producing cells after 48h. Antigen-specific proliferation after 5 days of stimulation was also measured by thymidine incorporation. Analyses showed low IL-4 responses against allogeneic third-party antigens in UCB transplant patients (Fig. 3A ) similar to that measured in adult healthy controls (22) . Conversely, against allogeneic host antigens, IL-4 production was strongly elevated in the UCB transplant patients, indicating a Th2 shift (Fig. 3A) . Strikingly however, none of the UCB patients produced significant amounts of IFN-␥ upon stimulation with stimulator cells expressing host antigens, whereas IFN-␥ production against third-party HLA disparate stimulator cells was strong to elevated in all patients tested (Fig. 3A) . These results were confirmed with similar patterns of UCB patient PBMC responsiveness observed in proliferation assays run in parallel, demonstrating absent to very low proliferation against cells expressing host antigens and moderate to strong proliferation against third-party antigens (Fig. 3A) . These results suggest immune tolerance specific for host antigens with observed Th2 skewing comparing MLC with transplant recipient vs. third party HLA irrelevant stimulator cells. The striking lack of IFN-␥ production upon stimulation with cells expressing host antigens, when compared to third-party stimulation, was confirmed as shown in Figure 3B (Pϭ0.045).
DISCUSSION
HLA disparity, including major and minor antigens, between the donor and recipient in allogeneic stem cell transplantation is an important determinant of GVHD. A higher incidence of acute GVHD has been observed in patients transplanted with HLA-matched unrelated grafts when compared with matched sibling grafts, despite HLA matching at high resolution molecular tissue typing. This may be attributable to reactivity of donor T cells with recipient minor histocompatibility antigens presented within the MHC complex (23) . Minor histocompatibility antigen disparity is expectedly greater between unrelated individuals. Early induction of transplantation tolerance is optimal for successful stem cell transplant outcomes, e.g. suppression or elimination of donor lymphocytes in the transplant patient's immune repertoire that are strongly reactive to self antigens; thereby leaving the majority of donor lymphocytes immunocompetent to perform the normal function of host protection after transplantation (24) .
Immune naivety of UCB allows successful transplanta- a Engraftment was first of three consecutive days to attain donor-derived absolute neutrophil count greater or equal to 500 cells/L. GVHD, graft versus host disease; CSA, cyclosporine; ␣-CD2 MoAB, anti-CD2 monoclonal antibody; CNS, central nervous system; MOF, multiple organ failure; NA, not available.
tion from unrelated donors despite HLA disparities at major loci without requirement of graft T cell depletion, and reconstitutes normal lymphohematopoietic function in the recipient over time (25) . Neonatal UCB graft T lymphocytes express a naive phenotype (CD45RA ϩ ), low level of activation markers, altered cytokine regulation, as well as susceptibility to tolerance induction in vitro (13, 14) . These phenotypic and functional characteristics of neonatal UCB graft accessory cells may account for the enhanced benefits for UCB recipients, including lower rates and severity of GVHD in the unrelated setting.
The clinical use of UCB grafts in transplantation for patients with hematologic malignancies and lacking a histocompatible donor, takes advantage of the unique characteristics of neonatal adaptive immunity. Clinical reports to date indicate lower incidence and severity of GVHD elicited by UCB grafts (2, 3, 5, 8) . Also, relevant murine studies show that neonatal mice are not immune deficient but biased towards Th2 immune responses (26) . Importantly, mice initially immunized as neonates mount Th2-dominant memory responses when re-exposed to the same antigens as adults; this offers one potential mechanism underlying the maintained tolerance observed in UCB stem cell transplant recipients in light of a maturing immune system. Human and mouse neonates under certain circumstances can develop Th1 lineage responses, e.g. responses to Mycobacterium bovis bacillus Calmette-Guerin (27, 28) , but commonly Th1 responses are limited in magnitude or partially biased to Th2-cell function (29 -31) . In addition, the quality of the immune response may be affected by the "high antigen load" that the host presents to the neonate engrafting immune system. It has been shown in neonatal mice that an adult-level dose of mouse leukemia virus leads to a Th2 response with no protection from disease, whereas a low level dose leads to Th1 deviation and protection from disease (32) .
It is unclear whether the reduced GVHD observed after UCB transplantation compared with bone marrow grafts obtained from adult donors is due to reduced graft lymphocyte number, altered recognition of recipient antigens by UCB donor T cells interacting with APC, and/or reduction in the amplification response of these naïve donor T cells, activated by recipient alloantigen presented within the context of MHC. These factors may serve to limit the cytokine and cellular cascade necessary to amplify UCB donor lymphocyte alloreactivity to recipient antigens, thereby limiting GVHD (33) . Alternatively, the low incidence of GVHD observed in recipients of HLA mismatched UCB may be related to the extensive immunosuppression from the myeloablative preparative regimens provided to ensure donor engraftment, and/or the lower dose of UCB graft lymphocytes infused. To determine whether the decreased alloresponsiveness of UCB lymphocytes could be attributable to pan-immunosuppression versus recipient-specific donor lymphocyte immune tolerance, we performed mixed lymphocyte cultures (MLC) during the early posttransplant period. Our studies identify that recipient-specific immune tolerance of UCB donor lymphocytes is generated in adult leukemia patients at early time points (3 months) after transplant. Notably, emerging UCB donor lymphocytes did not proliferate in response to recipient PBMC, yet maintained high proliferative responses to third party HLA-disparate allogeneic stimulator cells, indicating recipient-specific tolerance rather than panimmunosuppressed lymphocyte function. These observations were confirmed upon ELISPOT analyses of cytokine production by emerging donor UCB lymphocytes which was skewed toward Th2 (IL-4) production with minimal Th1 cytokines (IFN-␥) produced in the presence of recipient stimulator cells in the majority of patients analyzed. However, donor-derived circulating lymphocytes in UCB transplant recipients maintained the potential for normal Th1-predominant cytokine production including IFN-␥ in the presence of third party HLA-disparate allogeneic stimulator cells.
Without cell labeling we cannot specify whether circulating donor-derived lymphocytes were expanded from the infused graft, generated de novo from infused UCB stem cells, or whether components of both sources comprise circulating lymphocytes in UCB transplant patients at these early time points. Data previously reported supports the hypothesis that early lymphocyte recovery in UCB adult recipients is primarily due to expansion of infused graft lymphocytes and peripheral education rather than thymic-derived, with reduced TRECs and oligoclonal V beta repertoire expression observed in these patients (34) .
Studies in bone marrow transplant patients have indicated that GVHD may stem from clonal expansion of alloreactive T-cells (35) and humoral response generated by donor immune cell recognition of host MHC (36) . Because UCB graft T lymphocytes primarily express a naive CD4ϩCD45RAϩ phenotype, the mechanisms leading to immune tolerance may differ from observations in patients receiving conventional HLA matched stem cell transplants from adult donors containing graft T lymphocytes expressing memory phenotype (37, 38) . Clinical studies have demonstrated a lower incidence and severity of GVHD in patients receiving a UCB transplant, despite HLA mismatching of one or more loci (2, 8, 9, 12) , supporting the hypothesis that immune tolerance toward recipient antigens may be facilitated by unique features of UCB grafts obtained from neonates.
In summary, early circulating donor-derived peripheral blood lymphocytes in adult leukemia transplant patients infused with HLA-mismatched unrelated UCB stem cell grafts after treatment with full myeloablative conditioning appear immune tolerant to the recipient. UCB graft lymphocyte naivety may allow development of recipient-specific tolerance after unrelated allogeneic stem cell transplantation despite infusion of grafts mismatched at more than one major HLA loci. Further studies to understand the mechanisms of neonatal antigen presentation and lymphocyte maturation and development in UCB stem cell transplant recipients are warranted. 
